Nov 01, 2017 8:30 am EDT CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8
Oct 31, 2017 8:00 am EDT CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer
Oct 23, 2017 4:30 pm EDT CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis
Oct 09, 2017 8:00 am EDT CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting
Sep 11, 2017 8:00 am EDT CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis
Aug 15, 2017 8:30 am EDT CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology
Aug 10, 2017 4:01 pm EDT CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 07, 2017 8:00 am EDT CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10